

# RANA M. MAYS, M.D., FAAD

## Double Board Certified Dermatologist

*Medical | Autoimmune | Cosmetic | Hair Loss Dermatology Expert*

---



## CLINICAL AND WORK EXPERIENCE

### Founder & CEO, Mays Dermatology

Louisville, KY | Corona Del Mar, CA | 2017–Present

- Lead and created multi-location full in house Dermatology practice with expertise in medical, surgical, cosmetic, and hair loss Dermatology.
- Oversee patient care, clinical operations, research activities, and staff development.

### Owner & Clinical Instructor, Mays Dermatology (Formerly Houston Skin Associates)

Houston, TX | 2025–Present

- Partner and attending Dermatologist
- Train residents and fellows in advanced medical and cosmetic dermatology procedures.

### Principal Investigator for Alopecia Areata, Center for Clinical Studies

Houston, TX | 2025–Present

- Principal Investigator leading a clinical trial investigating novel therapies for alopecia areata, overseeing study design, patient enrollment, data collection, and regulatory compliance.
- Ensured adherence to protocol and contributed to advancing therapeutic options for hair loss.

### Principal & Sub-Investigator, Center for Clinical Studies

Webster, TX | 2015–2025

- Principal Investigator on numerous Phase II–III trials for psoriasis, eczema, acne, atopic dermatitis, and systemic therapies.
- Managed study design, regulatory submissions, and patient enrollment for over 50 industry-sponsored trials.

### Dermatology Associate, Dermatological Association of Texas

Houston, TX | 2015–2017

- Comprehensive dermatology care in high-volume group setting.

### Internal Medicine Hospitalist, Baptist East Hospital

Louisville, KY | 2010–2011

- Full-time inpatient care, including critical care, consult services, and acute management of complex cases.
- 

## AWARDS & HONORS

- **America's Top Dermatologist**
  - **Top Doctor** (*Physician peers -nominated*)
  - **Top Injector**
  - **"40 Under 40" Nominee, 2020** – Recognized by peers and patients for contributions to dermatologic education and expanding access to care
  - **Chief Resident**, Baylor College of Medicine (Ben Taub & VA Hospitals)
  - **98th Percentile** – American Board of Dermatology In-Service Exam
  - Internal Medicine Clinical Clerkship Award
  - University of Louisville Ashley R. McCullough Exceptional Honors Student Award
  - Kentucky Educational Excellence Full College Scholarship – 4 years
  - Golden Key International Honour Society – 4 years
  - Dean's List – 4 years
- 

## EDUCATION & MEDICAL TRAINING

**Baylor College of Medicine** — *Dermatology Residency*  
Houston, TX | 2012–2015

- Chief Resident, Ben Taub General Hospital and VA Medical Center
- 98th percentile, ABD In-Service Exam

**University of Louisville Hospital** — *Internal Medicine Residency*  
Louisville, KY | 2007–2010

**University of Louisville School of Medicine** — *M.D.*  
Louisville, KY | 2003–2007

**University of Louisville College of Arts & Sciences** — *B.S., Biology*  
Louisville, KY | 1999–2003

- Minor: Chemistry | Summa Cum Laude

**Study Abroad** — *Art & Architecture History*  
Spain & Portugal | 2002

---

## BOARD CERTIFICATIONS & PROFESSIONAL AFFILIATIONS

- **American Board of Dermatology**
- **American Board of Internal Medicine**
- **Fellow**, American Academy of Dermatology, American Academy of Dermatology (AAD), American Society for Dermatologic Surgery (ASDS), Skin Cancer Foundation, American Society of Aesthetic & Cosmetic Physicians (ASACP)

- **Member:** American Society of Dermatologic Surgery, Skin Cancer Foundation, California & Kentucky Medical Associations, Harris County Medical Society, Lupus Foundation, American College of Physicians

## RESEARCH

---

2025	Principal investigator Alopecia Areata, <i>Center for Clinical Studies</i>	<i>Houston, Texas</i>
	<ul style="list-style-type: none"> <li>● Led a clinical trial investigating novel therapies for alopecia areata, overseeing study design, patient enrollment, data collection, and regulatory compliance. Ensured adherence to protocol and contributed to advancing therapeutic options for hair loss.</li> </ul>	
2017	<i>Principal Investigator</i> <i>Foamix/ Center for Clinical Studies</i>	<i>Webster, Texas</i>
	<ul style="list-style-type: none"> <li>▪ <i>A Randomised, Multicenter, Double-blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-12).</i></li> </ul>	
2017	<i>Principal Investigator</i> <i>Oncobiologics/ Center for Clinical Studies</i>	<i>Webster, Texas</i>
	<ul style="list-style-type: none"> <li>▪ <i>A Randomised, Double-blind, Multicenter, Equivalence study of ONS-3010 and Humira for the treatment of patients with Moderate-to-Severe plaque psoriasis.</i></li> </ul>	
2017	<i>Principal Investigator</i> <i>Incyte/ Center for Clinical Studies</i>	<i>Webster, Texas</i>
	<ul style="list-style-type: none"> <li>▪ <i>A Phase 2 Randomised, Dose-Ranging, Vehicle Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults with Atopic Dermatitis.</i></li> </ul>	
2017	<i>Principal Investigator</i> <i>Sandoz/ Center for Clinical Studies</i>	<i>Webster, Texas</i>
	<ul style="list-style-type: none"> <li>▪ <i>A Randomised, Double-blind, Multi-Center, Two-Arm parallel-group Phase III study in patients with moderate to severe chronic plaque-type psoriasis to compare efficacy, safety, and immunogenicity of GP2018 to Remicade. , Actual Use study of dupilumab auto injector device in patients with Atopic Dermatitis.</i></li> </ul>	
2017	<i>Interim Principal Investigator / Subinvestigator</i> <i>Topstone/ Center for Clinical Studies</i>	<i>Webster, Texas</i>
	<ul style="list-style-type: none"> <li>▪ <i>A Randomised, Double-blind, Vehicle-Controlled, Phase IIb Study to Assess the Efficacy and Safety of Topically Applied DS107 Cream to Adults with Mild to Moderate Atopic Dermatitis.</i></li> </ul>	
2016	<i>Principal Investigator</i> <i>Incyte/ Center for Clinical Studies</i>	<i>Webster, Texas</i>
	<ul style="list-style-type: none"> <li>▪ <i>A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis</i></li> </ul>	

---

2016	<i>Interim Principal Investigator/ Subinvestigator</i> Glenmark/ Center for Clinical Studies	Webster, Texas
	<ul style="list-style-type: none"> <li>▪ <i>Subinvestigator for A Phase 2a, Double-Blind, Randomized, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis</i></li> </ul>	
2016	<i>Interim Principal Investigator/ Subinvestigator</i> UCB/ Center for Clinical Studies	Webster, Texas
	<ul style="list-style-type: none"> <li>▪ <i>Subinvestigator for A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS; PHASE 2B</i></li> </ul>	
2016	<i>Interim Principal Investigator/ Subinvestigator</i> UCB/ Center for Clinical Studies	Webster, Texas
	<ul style="list-style-type: none"> <li>▪ <i>Subinvestigator for MULTICENTER, 48-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS; PHASE 2B</i></li> </ul>	
2015	<i>Interim Principal Investigator/ Subinvestigator</i> Cutanea/ Center for Clinical Studies	Webster, Texas
	<ul style="list-style-type: none"> <li>▪ <i>Subinvestigator for a phase 3 open-label extension study to evaluate the long-term safety of Omiganan Topical Gel in subjects with rosacea.</i></li> </ul>	
2015	<i>Interim Principal Investigator/ Subinvestigator</i> Boehringer Ingelheim/ Center for Clinical Studies	Webster, Texas
	<ul style="list-style-type: none"> <li>▪ <i>Subinvestigator for BI 655066 versus placebo in a multicenter randomized double blind study in patients with moderate to severe plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and treatment.</i></li> </ul>	
2015	<i>Interim Principal Investigator/ Subinvestigator</i> Novartis/ Center for Clinical Studies	Webster, Texas
	<ul style="list-style-type: none"> <li>▪ <i>Subinvestigator for a randomized, double-blind, placebo-controlled parallel-group multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis.</i></li> </ul>	
2015	<i>Interim Principal Investigator/ Subinvestigator</i> Galderma/ Center for Clinical Studies	Webster, Texas
	<ul style="list-style-type: none"> <li>▪ <i>Subinvestigator for a multi-center, randomized, double-blind, parallel-group vehicle-controlled study to compare the efficacy and safety of CD5789 cream versus vehicle cream in subjects with acne vulgaris.</i></li> </ul>	
2015	<i>Interim Principal Investigator/ Subinvestigator</i> GlaxoSmithKline/ Center for Clinical Studies	Webster, Texas

---

	<ul style="list-style-type: none"> <li>▪ Subinvestigator for study 203121: a randomized, blinded, vehicle-controlled dose-finding study of GSK 2894512 Cream for the treatment of atopic dermatitis.</li> </ul>	
2015	<p><i>Interim Principal Investigator/ Subinvestigator</i>  GlaxoSmithKline/ Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for study 203120: a randomized, blinded, vehicle-controlled dose-finding study of GSK 2894512 Cream for the treatment of plaque psoriasis.</li> </ul>	Webster, Texas
2015	<p><i>Interim Principal Investigator/ Subinvestigator</i>  Lilly Chorus/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for A Randomized, Double-Blind, Placebo-Controlled, Phase 2 study to evaluate the safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis, protocol I4V-MC-JAHG (a)</li> </ul>	Webster, Texas
2015	<p><i>Interim Principal Investigator/ Subinvestigator</i>  Contravir/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster-Associated Pain</li> </ul>	Webster, Texas
2015	<p><i>Interim Principal Investigator/ Subinvestigator</i>  Eli Lilly/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Izekizumab dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis</li> </ul>	Webster, Texas
2015	<p><i>Interim Principal Investigator/ Subinvestigator</i>  Coherus 1420-02/ Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 versus Humira In Subjects with Chronic Plaque Psoriasis</li> </ul>	Webster, Texas
2015	<p><i>Interim Principal Investigator/ Subinvestigator</i>  Dermira PS0003/ Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-AND ACTIVE-CONTROLLED STUDY FOLLOWED BY A PLACEBO-CONTROLLED MAINTENANCE PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS</li> </ul>	Webster, Texas
2015	<p><i>Interim Principal Investigator/ Subinvestigator</i>  Merck MK-3222-010/ Center for Clinical Studies</p>	Webster, Texas

2015	<ul style="list-style-type: none"> <li>▪ Subinvestigator for a 64-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis</li> </ul>	
	<p><i>Interim Principal Investigator/ Subinvestigator</i> Merck MK-3222-011/ Center for Clinical Studies</p>	Webster, Texas
2015	<ul style="list-style-type: none"> <li>▪ Subinvestigator for a 52 Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-term Safety Extension Study in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis</li> </ul>	
	<p><i>Interim Principal Investigator/ Subinvestigator</i> Leo Pharma 1032/ Center for Clinical Studies</p>	Webster, Texas
2015	<ul style="list-style-type: none"> <li>▪ Subinvestigator for Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250cm<sup>2</sup> on the Chest</li> </ul>	
	<p><i>Interim Principal Investigator/ Subinvestigator</i> Leo Pharma 1193/ Center for Clinical Studies</p>	Webster, Texas
2015	<ul style="list-style-type: none"> <li>▪ Subinvestigator for Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up</li> </ul>	
	<p><i>Interim Principal Investigator/ Subinvestigator</i> Leo Pharma 1195/ Center for Clinical Studies</p>	Webster, Texas
2015	<ul style="list-style-type: none"> <li>▪ Subinvestigator for Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp including 12-month follow-up</li> </ul>	
	<p><i>Interim Principal Investigator/ Subinvestigator</i> Polynoma/ Center for Clinical Studies</p>	Webster, Texas
2015	<ul style="list-style-type: none"> <li>▪ Subinvestigator for a multicenter, randomized, double-blind, placebo and active comparator-controlled study evaluating the efficacy and safety of guselkumab in the treatment of subjects with moderate to severe plaque-type psoriasis.</li> </ul>	
	<p><i>Interim Principal Investigator/ Subinvestigator</i> Janssen/ Center for Clinical Studies</p>	Webster, Texas
2012	<ul style="list-style-type: none"> <li>▪ Subinvestigator for a phase 3 multicenter, randomized, double-blind, placebo and active comparator-controlled study evaluating the efficacy and safety of guselkumab in the treatment of subjects with moderate to severe plaque-type psoriasis.</li> </ul>	
	<p><i>Investigator</i> Veterans Affairs Hospital, Department of Dermatology</p>	Houston, Texas
2011	<ul style="list-style-type: none"> <li>▪ Investigator for an open label trial determining the clinical response to daily Vismodegib therapy in treatment of non-operable or metastatic basal cell carcinoma.</li> </ul>	
	<p><i>Subinvestigator</i> Veregen/Center for Clinical Studies</p>	Webster, Texas

2011	<ul style="list-style-type: none"> <li>Subinvestigator for an investigator-initiated, open-label, mechanism of action study examining the antiviral and immune-modulatory effects of Veregen (sinecatechins ointment, 15%) in patients with external genital warts.</li> </ul>	
	<p><i>Subinvestigator</i> Galderma/ Center for Clinical Studies</p>	Webster, Texas
2011	<ul style="list-style-type: none"> <li>Subinvestigator for a multi-center, randomized, double-blind, placebo-controlled, 3-arm parallel group study comparing the efficacy of CD2475/101 versus placebo and doxycycline in patients with inflammatory acne vulgaris.</li> </ul>	
	<p><i>Subinvestigator</i> 2011Celgene/ Center for Clinical Studies</p>	Webster, Texas
	<ul style="list-style-type: none"> <li>Subinvestigator for a phase 3, multicenter, randomized, double-blind, placebo-controlled efficacy and safety study of oral apremilast (CC-10004) in adults with moderate to severe plaque psoriasis.</li> </ul>	
2011	<p><i>Subinvestigator</i> Pfizer-Wyeth/Center for Clinical Studies</p>	Webster, Texas
	<ul style="list-style-type: none"> <li>Subinvestigator for a phase 4, multicenter, randomized, non-therapeutic interventional trial investigating prevalence of psoriatic arthritis in adults with psoriasis.</li> </ul>	
2011	<p><i>Subinvestigator</i> Celgene/Center for Clinical Studies</p>	Webster, Texas
	<ul style="list-style-type: none"> <li>Subinvestigator for a phase 3, multicenter, randomized, double-blind, parallel group, placebo-controlled study of two doses of apremilast in subjects with active psoriatic arthritis who have been previously treated with Disease-Modifying Anti-Rheumatic Drugs (DMARDs).</li> </ul>	
2011	<p><i>Subinvestigator</i> Abbott/Center for Clinical Studies</p>	Webster, Texas
	<ul style="list-style-type: none"> <li>Subinvestigator for a phase 3, multi-center, open-label study of briakinumab in patients with moderate to severe plaque psoriasis.</li> </ul>	
2011	<p><i>Subinvestigator</i> Amgen/Center for Clinical Studies</p>	Webster, Texas
	<ul style="list-style-type: none"> <li>Subinvestigator for a phase 2 open label safety and efficacy study of AMG-827, an IL-17 inhibitor, for treatment of moderate to severe plaque psoriasis.</li> </ul>	
2011	<p><i>Subinvestigator</i> Amgen/Center for Clinical Studies</p>	Webster, Texas
	<ul style="list-style-type: none"> <li>Subinvestigator for an observational post-marketing safety surveillance registry of etanercept for treatment of plaque-type psoriasis.</li> </ul>	
2011	<p><i>Subinvestigator</i> Novartis/Center for Clinical Studies</p>	Webster, Texas
	<ul style="list-style-type: none"> <li>Subinvestigator for a randomized, double-blind, placebo-controlled, multi-center study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks and to assess safety, tolerability, and long-term efficacy up to one year in subjects with moderate to severe chronic plaque psoriasis.</li> </ul>	
2011	<p><i>Subinvestigator</i> LEO/Center for Clinical Studies</p>	Webster, Texas
	<ul style="list-style-type: none"> <li>Subinvestigator for a phase 3 multi-center study comparing once daily treatment with calcipotriol plus betamethasone, betamethasone in its vehicle, calcipotriol in its vehicle, and the topical vehicle alone in subjects with psoriasis vulgaris on non-scalp regions of the body.</li> </ul>	

2011	<p><i>Subinvestigator</i> Webster, Texas Amgen/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of combination of topical clobetasol and etanercept in subjects with moderate to severe plaque psoriasis.</li> </ul>
2011	<p><i>Subinvestigator</i> Webster, Texas NeurogesX/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for a multi-center, randomized, double-blind, controlled study to evaluate the safety, tolerability, and preliminary efficacy of two capsaicin concentration variations of NGX-1998 (10% or 20%) in subjects with postherpetic neuralgia (PHN).</li> </ul>
2011	<p><i>Subinvestigator</i> Webster, Texas Intendis/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for a phase 2, double-blind, randomized, vehicle-controlled, multi-center, multi-national, parallel-group study of the efficacy and safety of ZK 245186 (selective glucocorticoid receptor agonist) ointment in concentrations of 0.01, 0.03, and 0.1 % over 4 weeks in patients with atopic dermatitis.</li> </ul>
2011	<p><i>Subinvestigator</i> Webster, Texas Amgen/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for an open label study to evaluate the efficacy of etanercept in subjects with moderate to severe plaque psoriasis who have lost a satisfactory response to adalimumab.</li> </ul>
2011	<p><i>Subinvestigator</i> Webster, Texas Centocor/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for a phase 2, multicenter, randomized, placebo-and-active comparator-controlled trial to evaluate the efficacy and safety of CNT-1959 in subjects with moderate to severe plaque psoriasis.</li> </ul>
2011	<p><i>Subinvestigator</i> Webster, Texas Pfizer/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for a phase 3, multicenter, open-label study of long-term efficacy, safety and tolerability of CP-690,550 (tofacitinib) in subjects with moderate to severe chronic plaque psoriasis.</li> </ul>
2011	<p><i>Subinvestigator</i> Webster, Texas Genocea/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for a phase 1/2a, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety and immunogenicity of a HSV-2 vaccine containing Matrix M2 adjuvant in patients with genital HSV.</li> </ul>
2011	<p><i>Subinvestigator</i> Webster, Texas Maruho/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for a randomized, placebo-controlled, double-blind, parallel-group, multi-center phase 2b dose finding study of M518101 (vitamin D derivative) in subjects with plaque psoriasis.</li> </ul>
2011	<p><i>Subinvestigator</i> Webster, Texas ApoPharma/Center for Clinical Studies</p> <ul style="list-style-type: none"> <li>▪ Subinvestigator for a phase 2, randomized, placebo-controlled, double-blind, multi-center, multiple sequential escalating study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Apo805K1</li> </ul>

(organic salt of thymodepressin) in subjects with moderate to severe chronic plaque psoriasis.

- |           |  |                      |
|-----------|--|----------------------|
| 2011      | <i>Subinvestigator</i><br>Novum/Center for Clinical Studies  | Webster, Texas       |
|           | <ul style="list-style-type: none"><li>Subinvestigator for a randomized, placebo-controlled, double-blind, multi-center study comparing metronidazole topical gel 1% to Metrogel® (metronidazole gel) 1 % in the treatment of moderate to severe rosacea.</li></ul>   |                      |
| 2011      | <i>Subinvestigator</i><br>Galderma/Center for Clinical Studies   | Webster, Texas       |
|           | <ul style="list-style-type: none"><li>Subinvestigator for a phase 3, randomized, placebo-controlled, double-blind, vehicle controlled, parallel group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular rosacea.</li></ul>   |                      |
| 2011      | <i>Primary Investigator, Study Designer</i><br>Center for Clinical Studies   | Webster, Texas       |
|           | <ul style="list-style-type: none"><li>Designed an original, case-controlled, retrospective study investigating the effects of gender, stress, and age on the incidence of postherpetic neuralgia (PHN) in patients with acute herpes zoster.</li></ul>   |                      |
| 2011      | <i>Clinical Investigator</i><br>NASA/ Center for Clinical Studies  | Webster, Texas       |
|           | <ul style="list-style-type: none"><li>Primary clinical investigator in a collaborative study with NASA scientists, analyzing the persistence of varicella zoster DNA in saliva of patients with C and T dermatomal herpes zoster. Involved in recruiting and treating subjects, obtaining samples for DNA analysis, collecting data, and submitting IRB documents.</li></ul>   |                      |
| 2008-2010 | <i>Primary Investigator</i><br>Melanoma Lab, James Graham Brown Cancer Center  | Louisville, Kentucky |
|           | <ul style="list-style-type: none"><li>Investigated the efficacy of AS1411, Pu27 and Bcl-2 quadriplex DNA molecules on Mel 2 and Mel 28 human melanoma cell lines (N-ras and BRAF negative) and the potential mechanism of action on melanoma oncogene transcription and enolase activity. Formulated the original design for this in-vitro study in collaboration with the Department of Medical Oncology.</li></ul> |                      |
| 2006-2007 | <i>Clinical Investigator</i><br>Sunbelt Melanoma Trial, Department of Surgical Oncology  | Louisville, Kentucky |
|           | <ul style="list-style-type: none"><li>Clinical investigator in a prospective, randomized, multi-center trial involving the USA and Canada. Investigated melanoma prognosis, morbidity, and mortality using analysis of sentinel lymph node (SLN) biopsies.</li></ul>   |                      |
| 2004      | <i>Primary Investigator</i><br>Division of Heart and Lung Transplant, Jewish Heart and Lung Center   | Louisville, Kentucky |
|           | <ul style="list-style-type: none"><li>Primary investigator in a prospective clinical study on health insurance coverage and its correlation to access to heart transplantation.</li></ul>  |                      |
| 2004      | <i>Clinical Investigator</i><br>Division of Cardiothoracic Surgery, University of Louisville   | Louisville, Kentucky |
|           | <ul style="list-style-type: none"><li>Primary clinical investigator in a retrospective study on left ventricular assist device (LVAD) implantation in cow models; analyzed different methods for diagnosis of patent foramen ovale during LVAD implantation.</li></ul>   |                      |
| 2001      | <i>Primary Investigator</i><br>National Eye Institute, National Institute of Health<br>Ocular Therapeutics Lab, Sinai Sato, MD, PhD  | Bethesda, Maryland   |

- Primary investigator in an *in vitro* study analyzing the role of retinal capillary pericytes in the pathogenesis of diabetic retinopathy and the use of pericyte-cell DNA as a potential therapy for the prevention of diabetic retinopathy.

## GRANTS

---

**Mays RM**, Tying SK. Efficacy and Safety of Topical Taclonex® under Glove-Occlusion in the Treatment of Severe Chronic Hand Eczema as Compared to Baseline: An Open Label Study. LEO Pharmaceuticals Investigator Initiated Grant. Grant status: Accepted.

**Mays RM**, Tying SK. Analysis of Postherpetic Neuralgia Pain after Combination Treatment with Extended Release Gabapentin (Horizant®) and Valacyclovir in Patients with Acute Herpes Zoster Compared to Active Controls; A Single-Blinded, Randomized, Controlled Study. GSK Investigator Initiated Research. Grant status: In review.

## PUBLICATIONS

---

**Mays RM**, Gordon RA, Lapolla WJ, Tying SK. Current Developments in Viral Skin Diseases. *Current Dermatology Reports*. 2012. DOI: 10.1007/s13671-011-0002-6.

**Mays RM**, Gordon RA, Javed S, Wilson JM, LaPolla WJ, Kjar N, Tying SK. Viral Diseases. In: *Imported Skin Diseases*. Wiley-Blackwell ; 2012 (2): 123-149.

**Mays RM**, Gordon RA, Wilson JM, Silapunt S. New Antibiotic Therapies in Acne and Rosacea. In Issue: New Antibiotics Important to the Dermatologists. Ed. Tying SK. *Dermatologic Therapy*. 2012; 25 (1): 23-27.

**Mays RM**, Petersen ET, Gordon RA, Tying SK. Herpes Zoster Virus. In: *Treatment of Skin Disease*. 4<sup>th</sup> ed. Elsevier Ltd. 2014: 311-314.

**Mays RM**, Curry JH, Kim K, Arora A, Tsai K, Khan F, Ramirez-Fort M, and Ciurea A. Eruptive Squamous Cell Carcinomas after Vemurafenib Therapy. *Journal of Cutaneous Medicine & Surgery*. 2013 Nov-Dec;17(6):419-22..

**Mays RM**, Gordon RA, LaPolla WJ, Wilson JM, Galfione SK, Sra KK, Tying SK. Persistent Erythematous Plaque after Minor Trauma in an Immunocompromised Woman. *Dermatology Online Journal*. 2012 Apr 15;18(4):2.

**Mays RM**, Gordon RA, Durham KC, Tying SK. Rocky Mountain Spotted Fever in a Patient Treated with Anti-TNF alpha Inhibitors. *Dermatol Online J*. 2013 Mar 15;19(3):7.

**Majd RE**, Kavarana MN, Dowling RD. Improved Technique to Diagnose a Patent Foramen Ovale During Left Ventricular Assist Device Insertion. *Annals of Thoracic Surgery*. 2006; 82 (5): 1917-18.

**Mays, RM**, Gordon RA, Durham KC, Tying SK. An Immunocompromised Man with Fever and Diffuse Macular Eruption. *Dermatology Online Journal*. Publication status: In press.

**Mays RM**, Gordon RA, Lapolla WJ, Tying SK. Herpes Zoster Associated with Combination of Physical Stress and Genetic Risk and a Potential New Therapy for Post Herpetic Neuralgia. *Clinical Virology*. Publication status: In press.

**Mays, RM**, Gordon RA, Lapolla WJ, Mendoza N, Tying SK. Viral Diseases. In: *Dermatology: A Pictorial Review*. 3<sup>rd</sup> ed. McGraw Hill. Publication status: In Press.

**Mays RM**, Murthy RK, Gordon RA, Bangert, S., Lapolla, WJ Hassan, A., Rapini, R., Tying SK. Diffuse Large B-Cell Lymphoma at the Site of a Herpes Zoster Scar. *World Journal of Oncology*. Publication status: In press.

Chon S, Hung DQ, **Mays RM**, Gordon RA, Tying SK. Antibiotic Overuse and Resistance in Dermatology. In Issue: New Antibiotics Important to the Dermatologists. Ed. Tying SK. *Dermatologic Therapy*. 2012; 25 (1): 55-69.

Sambrano B, Gordon RA, **Mays RM**, Scheinfeld N. Intravenous Antibiotics in Dermatology. In Issue: New Antibiotics Important to the Dermatologists. Ed. Tying SK. *Dermatologic Therapy*. 2012; 25 (1): 70-81.

Javed S, **Mays RM**, Tying SK. Clinical Characteristics and Awareness of Skin Cancer in Hispanic Patients. *Dermatology Online Journal*. 2013 Sept 19(9): 12.

Khan F, **Mays R**, Brooks J, Tying S. In: *Text Atlas of Obstetric Dermatology*, Kroumpouzou G, ed. Philadelphia: Wolters Kluwer Health - Lippincott Williams & Wilkins; 2014 (14): 208-219.

Gordon RA, **Mays RM**, Lapolla WJ. Antibiotics Used in Non-Bacterial Dermatologic Conditions. In Issue: New antibiotics Important to the Dermatologists. Ed. Tying SK. *Dermatologic Therapy*. 2012; 25 (1): 38-54.

Javed S, **Mays RM**, Tying SK. Herpes Zoster Vaccine Awareness Among Individuals  $\geq 50$  Years of Age and its Implications on Vaccination. *Dermatology Online Journal*. 2012 Aug; 15;18 (8):2.

Gordon RA, **Mays RM**, Lapolla WJ, Galfione S, Tying SK. Herpes Simplex Virus. In: J. Zeichner (Ed.), *Acneiform Eruptions in Dermatology: A Differential Diagnosis*. Springer Publishing Company. 2014: 85-95.

Gordon RA, **Mays RM**, Lapolla WJ, Tying SK. Varicella Zoster Virus. In: J. Zeichner (Ed.), *Acneiform Eruptions in Dermatology: A Differential Diagnosis*. Springer Publishing Company. 2014: 95-107.

Gordon RA, **Mays RM**, Doan H, Lapolla WJ, Tying SK. Biologic Use in Dermatology and the Associated Risk of Infection. *Skin Therapy Letter*. 2012; 17(5): 1-4.

Gordon RA, **Mays RM**, Lapolla WJ, Tying SK. Herpes Zoster Duplex Bilateralis in an Immunocompetent Woman: Is Gender a Risk Factor?" *Population and Health Management*. 2012; 15 (6): 1564-66.

Gordon RA, **Mays RM**, Lapolla W, Tying SK. Human Papillomavirus: Epidemiology and Clinical Features of Virus Infection and Related Cancer. In: *Viruses and Human Cancer*. Springer Publishing. Publication status: In Press.

Gordon RA, Sutton DA, Thompson EH, Shrikanth V, Verkley GJ, Stielow JB, **Mays RM**, Oleske D, Morrison LK, Lapolla WJ, Galfione S, Tying S, Samathanam CA, Fu J, Wickes BL, Mulanovich V, Wanger A, Arias CA. Cutaneous Phaeoerythromycosis caused by *Paraconiothyrium cyclothyrioides*. *J Clin Microbiol*. 2012 [Epub ahead of print] PubMed PMID: 22915609.

Durham KC, **Mays RM**, Gordon RA, Hicks LD, Colome M. Cutaneous Metastatic Hepatocellular Carcinoma of the Head and Neck: A Case Report and Review of Literature. *Journal of Cutaneous Pathology*. Publication status: Provisional Accepted.

Gordon RA, **Mays RM**, Lapolla WJ, Tying SK. Herpes Simplex Virus. In: *Treatment of Skin Disease*. 4<sup>th</sup> ed. Elsevier Ltd. 2014: 304-308.

## **PRESENTATIONS**

---

Psoriasis and Systemic Therapy. University of Texas Medical Branch Galveston, Department of Family Practice. February 2017

A novel therapy in Psoriasis Treatment. You have Options. Baylor College of Medicine, Department of Physician Education. July 2016

Mays, Rana. Dermatologic Manifestations of Internal Diseases. Baylor College of Medicine Physicians Assistant Program Lectures. April 2014.

Mays, Rana. Skin and the Sun. Baylor College of Medicine Annual Dermatology Medical Student Lecture. August 2013.

Mays, Rana. Skinternal Medicine. Baylor College of Medicine Dermatology Basic Science Lecture. May 2013.

Mays, Rana. Antibiotics, Antivirals, and Antifungals. Baylor College of Medicine Dermatology Basic Science Lecture. May 2012.

Tamirisa A, Downing C, Mays R. Clinical Characteristics of Coxsackievirus A6 Associated Hand, Foot, and Mouth Disease in Adults. Texas Dermatological Society Meeting. Galveston, TX. October 2013.

Mays, Rana. The Impact of Additional Dose of Zoster Vaccine in Individuals Previously Vaccinated. Presented at: American Academy of Dermatology 70<sup>th</sup> Annual Meeting, San Diego, CA. March 2012.

Mays, Rana. Skin Cancer in Minorities: Incidence, Characteristics, & Awareness. Presented at: Houston Dermatologic Society Meeting, Houston, TX; February 2012.

Kim S, Gordon RA, Mays RM, and Tyring SK. Skin Cancer Awareness in White Hispanics and Non Hispanic Whites. Poster presented at: American Academy of Dermatology 71<sup>th</sup> Annual Meeting, Miami FL. March 2013.

Mays, Rana. A Polymorphous Mucocutaneous Eruption in a Patient with End Stage Renal Disease. Presented at: Houston Dermatologic Society Meeting. Houston, TX; December 2011.

Mays, Rana. Opportunistic Fungal Infections in Non-AIDS Patients. Presented at: Texas Dermatologic Society. Temple, TX; September 2011.

Mays, Rana. Persistence of Varicella Zoster DNA in Saliva after Herpes Zoster. Poster Presented at: Texas Dermatologic Society. Temple, TX; September 2011.

Mays, Rana. Diffuse Erythematous Macules in an Immunosuppressed Man. Presented at: Houston Dermatologic Society Meeting. Houston, TX; September 2011.

Mays, Rana. Persistent Erythematous Plaque in an Elderly Immunocompromised Woman: A Case Report. Presented at: Houston Dermatologic Society Meeting. Houston, TX; August 2011.

Mays, Rana. High Dose Intralesional IL-2 in Combination with Topical Imiquimod Therapy for Cutaneous Melanoma Metastasis; A Case Report and Review. Presented at: Department of Dermatology, University of Texas Medical School at Houston. Houston, TX; September 2009.

Mays, Rana. Complications & Management of MRSA Skin and Soft Tissue Infections. Poster presented at: ACP Regional Chapter Meeting. Chicago, IL; March 2009.

Mays, Rana. Hypercalcemia of Malignancy. Presented at: Annual Shakertown Internal Medicine Symposium. Shakertown, KY; March 2010.

Mays, Rana. Presented at: Department of Internal Medicine Morning Report.

- Takotsubo cardiomyopathy; March 2010
- Sulfonylurea Toxicity: Clinical Features, Prognosis, and Treatment; January 2010.
- Systemic Lupus Erythematosus in an Elderly Female Presenting with Acute Cerebral Vascular Accident; October 2009.
- Management of Bacterial Meningitis in Adults; August 2009.
- Choledocholithiasis: Diagnosis and Therapy; October 2008.
- Syncope; Diagnosis, Culprits, and Treatment; February 2008.

- Mays, Rana. Presented at: Veterans Affairs Resident CCU Rounds.
- Digoxin Use for Rate Control of Atrial Fibrillation in Class III & IV Heart Failure Patients; June 2010.
  - Prompt Initiation of Statin Therapy in Acute Coronary Syndrome; November 2009.

Mays, Rana. Medical ICU Monthly Report.

- Strict Diabetic Control in ICU Patients: Effects on Morbidity and Mortality; May 2010.
- IVIG Use for the Treatment of Acute Renal Failure in Wegener's Granulomatosis. December 2009.
- New Guidelines in the Management of Septic Shock; January 2008

Mays, Rana. Sarcoidosis: Clinical Presentation, Diagnosis, & Treatment. University of Louisville Continuity Clinic Resident Discussion; May 2010.

Mays, Rana. Evaluation of a Patient with Abnormal Thyroid Function Tests. Presented at: University of Louisville Continuity Clinic Resident Discussion; November 2009.

Mays, Rana. New Recommendations and Review of Literature in the Management of Type II Diabetes. Presented at: University of Louisville Continuity Clinic Resident Discussion; July 2009.

Mays, Rana. Comparison of Colonoscopy Versus Fecal Occult Blood Testing in Colon Cancer Prevention. Presented at: Veterans Affairs PRIME Clinic Meeting; February 2010.

Mays, Rana. Vitamin D Deficiency: New Research and Current Recommendations. Presented at: Veterans Affairs PRIME Clinic Meeting; April 2009.

Mays, Rana. Aspirin Versus Clopidogrel in Secondary Stroke Prevention; A Review of Literature. Presented at: Veteran Affairs PRIME Clinic Meeting; December 2008.

Mays, Rana. Prostate Specific Antigen (PSA) Screening and the Effect on Cancer Mortality. Presented at: University of Louisville Internal Medicine Journal Club; March 2008.

Majd, Rana. Prospective Evaluation of the Impact of Insurance Coverage on Access To Heart Transplantation. Poster presented at: Annual Research Louisville Symposium; July 2004.

Majd, Rana. Retinal Capillary Pericytes and their Role in Diabetic Retinopathy. Poster presented at: National Eye Institute Ocular Therapeutics Summer Seminar; August 2001.

Majd, Rana, Sato Sinai. Retinal Capillary Pericytes as a New Pharmacologic Target For Diabetic Retinopathy. Poster presented at: National Eye Institute Ocular Therapeutics Summer Seminar; August 2001

2014- Present *Cosmetics Liaison*

Baylor College of Medicine, Dermatology

Houston, TX

- Elected by members of the residency. In charge of monthly resident cosmetics clinic for hands on teaching of toxin, filler, laser, peels, and various other cosmetics procedures.

2012-13 *Physician Volunteer*

Houston, TX

Skin Cancer Screening

- Served as a physician volunteer evaluating over one hundred skin cancer screening patients at local clinics in Houston and Cypress.

2011 *Physician Volunteer*

Houston, TX

Dept. of Dermatology, University of Texas Medical School at Houston

- Instructed medical students on the use of dermatologic terminology in a practical workshop as part of their 2<sup>nd</sup> year curriculum.

2011 *Physician Speaker*

Houston, TX

Dermatology Nurses Association, Gulf Coast Chapter

- Discussed current clinical trials and investigational therapies for the treatment of psoriasis and psoriatic arthritis.
- 2008-2010     *Elected Physician Representative*     Louisville, KY  
 Graduate Medical Education House Staff Council
  - Represented the Internal Medicine residency program at monthly meetings to address graduate medical education issues.
- 2010     *Elected Member, Antibiotic Utilization Committee, University Hospital*     Louisville, KY
  - Involved in analyzing the hospital’s “antibiogram” and setting guidelines for prevention of antibiotic over-use and resistance in collaboration with infectious disease, microbiology, and in-patient pharmacy.
- 2009     *Physician Volunteer; Wings clinic*     Louisville, KY
  - Served as physician volunteer for the care of HIV & AIDS patients.
- 2009     *Volunteer, The Skin Cancer Screening & Benefit Walk*     Louisville, KY
- 2007-2008     *Elected representative, Internal Medicine Resident Steering Committee*     Louisville, KY
- 2006-2007     *Instructor, University of Louisville School of Medicine USMLE study sessions*     Louisville, KY
  - Served as a group-study instructor for 2<sup>nd</sup> year medical students in the USMLE exam preparation.
- 2004-2005     *Director, HOPE clinic for Women and Children*     Louisville, KY
  - Served as director in this medical-student-run clinic for indigent patients in the community.
  - Scheduled volunteer attending physicians, provided care for adult and pediatric patients, and performed physical exams and immunizations.
- 2003-2004     *Committee Leader, Action committee; American Medical Student Association*     Louisville, KY  
 Served as the elected leader for the “Community and Environmental Health Action Committee”.
- 2001-2003     *President & Founder, ESL Volunteers*     Louisville, KY
  - Founded this organization in collaboration with the U of L International Department. Organized and recruited volunteers at the University of Louisville to teach English to local middle school students enrolled in English as a Second Language (ESL) classes.
- 2001-2003     *Tutor, University of Louisville REACH Tutoring, Athletics Department*     Louisville, KY
  - Tutored student athletes in the subjects of Biology, Chemistry, Microbiology, Physiology, and Histology.

## LANGUAGES

- Farsi (Fluent)
- French (Proficient)

## INTERESTS

Mother of 3 | Chess | Yoga | Travel & Culinary Exploration | Painting (Oil & Watercolor)